Sun Pharma arm enters pact with China Medical System

Sun Pharmaceutical Industries Ltd. has entered into a licensing agreement with China medical System Holdings Ltd (CMS) through its wholly owned subsidiary to enter the market of Greater China for its dermatology products. China medical system will pay licensing fee to Sun pharma for an initial upfront payment, regulatory and sales milestone payments, and royalties on net sales, the terms of which are confidential to the company

Sun pharma holds two major products: Tildrakizumab and Cyclosporine as their leading products. This agreement will be for manufacturing and commercialization of the biological product Tildrakizumab, in Greater China that will include Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan.

This agreement is an achievement for Sun Pharma as it enters China’s market which is considered one of the important markets for pharmaceuticals. Sun pharma will continue to build up its therapeutical domain and focus on unmet need. It will focus on dermatology product like Tildrakizumab and ophthalmology franchise by Cyclosporine as its lead product.

The agreement is for initial 15 years from the commercialization with an extension for additional 3 years depending on the terms and conditions in the agreement.

CMS will be held responsible for the development, commercializing and regulatory filing of the product in China.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.